MeSH tree: D08.811.913.696.620.682
In 2016, University of Pittsburgh researchers Dr. Farzad Esni, Ph.D., and Jing Hu, Ph.D., did an experiment in mice where they deleted one of two copies of the gene encoding an enzyme called focal adhesion kinase (FAK). They ...
May 6, 2024
0
94
Glioblastoma is an often fatal form of brain cancer, with only 5% of patients surviving beyond five years. The cancer is difficult to treat and almost always becomes resistant to treatment. As a result, recurrence of glioblastoma ...
May 6, 2024
0
43
By the time cancer is diagnosed, a lot has already happened behind the scenes. Although cancers are classed into early and late stages for clinical purposes, even an "early" stage tumor is the result of many previous, undetectable ...
May 6, 2024
0
40
The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Apr 23, 2024
0
35
New research conducted in mice offers insights into what's going on at the molecular level that could cause people with diabetes to develop Alzheimer's disease.
Mar 25, 2024
0
47
A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients.
Mar 14, 2024
0
57
A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget.
Feb 7, 2024
0
40
Many cancers, including some types of breast cancer, are driven by alterations in the activity of cellular enzymes called kinases. Therapies that directly inhibit these cancer-promoting activities have proven to be effective ...
Jan 16, 2024
0
19
Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death worldwide. It is marked by lung damage that is lasting and incurable, leaving lung transplantation as the only viable treatment option. Unfortunately, ...
Jan 5, 2024
0
40
Last month, the U.S. Food and Drug Administration (FDA) approved the use of the drug capivasertib, in combination with a current cancer treatment called fulvestrant for patients with the most common type of breast cancer, ...
Dec 21, 2023
0
43
